Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.
Abivax (Euronext Paris: ABVX), una società biotecnologica in fase clinica, ha annunciato la ripresa delle negoziazioni delle sue azioni ordinarie su Euronext Paris a partire dal 24 luglio 2025, alle 15:30 CEST.
La sospensione delle negoziazioni, iniziata alle 9:00 CEST dello stesso giorno, è stata attuata per facilitare il processo di allocazione e l'annuncio del prezzo dell'offerta di American Depositary Shares (ADS) della società negli Stati Uniti. Ogni ADS rappresenta un'azione ordinaria con un valore nominale di €0,01.
Abivax (Euronext Paris: ABVX), una empresa biotecnológica en fase clínica, anunció la reanudación de la negociación de sus acciones ordinarias en Euronext Paris a partir del 24 de julio de 2025, a las 15:30 CEST.
La suspensión de la negociación, que comenzó a las 9:00 CEST del mismo día, se implementó para facilitar el proceso de asignación y el anuncio del precio de la oferta de American Depositary Shares (ADS) de la compañía en Estados Unidos. Cada ADS representa una acción ordinaria con un valor nominal de €0,01.
Abivax (Euronext Paris: ABVX)는 임상 단계의 바이오테크 기업으로, 2025년 7월 24일 오후 3시 30분 CEST부터 Euronext Paris에서 보통주 거래가 재개됨을 발표했습니다.
동일한 날 오전 9시 CEST부터 시작된 거래 중단은 미국에서 회사의 American Depositary Shares (ADS) 공모의 배정 절차 및 가격 발표를 원활하게 하기 위해 시행되었습니다. 각 ADS는 액면가 €0.01의 보통주 1주를 나타냅니다.
Abivax (Euronext Paris : ABVX), une société de biotechnologie en phase clinique, a annoncé la reprise de la cotation de ses actions ordinaires sur Euronext Paris à compter du 24 juillet 2025 à 15h30 CEST.
La suspension des échanges, débutée à 9h00 CEST le même jour, a été mise en place pour faciliter le processus d’allocation et l’annonce du prix de l’offre des American Depositary Shares (ADS) de la société aux États-Unis. Chaque ADS représente une action ordinaire d’une valeur nominale de 0,01 €.
Abivax (Euronext Paris: ABVX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, gab die Wiederaufnahme des Handels mit seinen Stammaktien an der Euronext Paris ab dem 24. Juli 2025 um 15:30 Uhr MESZ bekannt.
Der Handelsstopp, der am selben Tag um 9:00 Uhr MESZ begann, wurde eingerichtet, um den Zuteilungsprozess und die Bekanntgabe des Preises des American Depositary Shares (ADS)-Angebots des Unternehmens in den Vereinigten Staaten zu erleichtern. Jede ADS entspricht einer Stammaktie mit einem Nennwert von €0,01.
- None.
- Potential dilution for existing shareholders through ADS offering
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST.
Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 |
***
Disclaimer
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FAQ
When will Abivax (ABVX) resume trading on Euronext Paris?
Why was Abivax (ABVX) stock trading halted?
What is the conversion ratio for Abivax's American Depositary Shares?
What is Abivax's main business focus?
